Adelaide researchers have taken a step closer to the development of a universal flu vaccine, with results of a recent study showing that a vaccine delivered by a simple nasal spray could provide protection against influenza.
University of Adelaide…
Nasal congestion can be a sign of severe asthma, which means that healthcare professionals should be extra vigilant when it comes to nasal complaints. Furthermore, more severe asthma appears to be more common than previously thought, reveals a study…
SAN DIEGO — (December 9, 2010) — A La Jolla Institute team, led by leading type 1 diabetes researcher Matthias von Herrath, M.D., has demonstrated the effectiveness of a recently developed computer model in predicting key information about nas…
CHAPEL HILL — Flu vaccine will soon be available at local pharmacies and doctor’s offices, and government officials are urging everyone over 6 months of age to receive it. This year’s vaccine protects against H1N1 and two other strains of season…
Mayo Clinic yesterday received broad patent coverage for a new treatment of chronic rhinosinusitis (CRS), commonly called “sinus infection,” a disease that annually affects 32 million adults in the United States and currently has no Food and Drug Administration-approved treatment. Studies at Mayo Clinic have found the cause of CRS — a reaction to certain fungi — and demonstrated that the delivery of antifungal drugs directly into the nose and sinuses is safe and significantly reduces patients? symptoms. Improvements in asthma symptoms were noted in the same patient group. Past medical treatments for chronic sinus infections have been unsuccessful or produced severe side effects.
A Canadian biomedical company said it has confirmed that a nasal vaccine protects mice against pneumonic Plague caused by lethal aerosol infection. In a series of experiments performed by the US Army Medical and Materiel Command at Fort Detrick, Maryland, in collaboration with ID Biomedical, mice nasally immunized with Plague antigen formulated with the Proteosome technology were completely protected against lethality (100%) even when the dose of Plague antigen was ten-fold lower than ever previously given nasally. In marked contrast, none of the control mice given nasal solution without vaccine antigen survived.